Skip to main content

ADC Therapeutics SA

corporate_fare Company Profile

ADC Therapeutics SA

ADCT·NYSE·Life Sciences·CIK 0001771910

ADC Therapeutics is a commercial-stage global company focused on antibody drug conjugates (ADCs). The company's primary product is ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. ZYNLONTA has received accelerated approval from the U.S. Food and Drug Administration (FDA) and conditional approval from the European Commission, China National Medical Products Administration (NMPA), and Health Canada. It is approved for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. ADC Therapeutics is expanding ZYNLONTA internationally and into earlier lines of DLBCL through the LOTIS-5 confirmatory Phase 3 clinical trial (rituximab combination) and LOTIS-7 Phase 1b clinical trial (bispecific combination). The company is also exploring ZYNLONTA's use in indolent lymphomas, including marginal zone lymphoma (MZL) and follicular lymphoma (FL), through investigator-initiated trials (IITs). Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics manages specialized capabilities spanning clinical development, manufacturing, and commercialization. The company completed IND-enabling activities for ADCT-241, an exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC, at the end of 2025. ADC Therapeutics utilizes its in-house chemistry, manufacturing and controls (CMC) capabilities and an external manufacturing network of third-party contract manufacturing organizations (CMOs) for highly potent molecules and complex biologics.

ADC Therapeutics SA (NYSE:ADCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for ADCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ADCT spans 8-K, S-4, 10-Q, DEF 14A.

Recent high-impact activity:

  • ADC Therapeutics Q3 Revenue Jumps to $21.0M, Cash Runway Extended Into 2029
  • Q3 Revenue Jumps 33% to $21M as Restructuring Extends Cash Runway Into 2029
  • ADC Therapeutics Reports 88.7% ORR in LOTIS-7 and Preliminary Q3 Revenue of $21M
  • ADC Therapeutics Files S-4 for Switzerland-to-Delaware Redomiciliation, Shareholder Vote Required
  • ADC Therapeutics Restructures: $86.6M PIPE, $70M Debt Paydown, HCR Royalty Rework

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$81.36M
Net Income
-$142.62M
Diluted EPS
-$1.12
Op. Cash Flow
-$141.17M
Free Cash Flow
-$141.44M
Gross Profit
$75.56M
Operating Income
-$121.5M
Cash & Equivalents
$261.34M
Total Debt
$3M
Debt / Equity
-0.02×
Net Margin
-175.3%
Shares Outstanding
125.75M sh
Source: 10-K · filed 2026-03-10 · accession 0001628280-26-016491

Short Interest & Short Volume

6.66 days to cover

FINRA reported short interest of 6,427,616 shares in ADCT as of the October 30, 2026 settlement, a 1.4% increase from the prior period — about 6.7 days to cover at its recent average daily volume. On November 20, 2026, 56.1% of ADCT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,427,616 shares as of October 30, 2026
Change vs prior period▲ 1.4%
Days to cover6.66 at avg daily volume of 964,848
Daily short volume (FINRA facilities)56.1% of 414,769 shares on November 20, 2026
5-day average short volume52.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ADCT, detected from its recent SEC filings · based on capital-structure filings through 2026-10-13.

1 shelf registration

$86.6M PIPE at Deep Discount · Massive Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$1.28
52-week range · as of 2026-11-09 $0.7796 – $4.98
Market cap
$180.05M
Volume
1.1M (0.8× avg)
3-mo avg 1.3M
Live data · 2026-11-21 04:06 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed ADCT - Latest Insights

ADCT
Nov 09, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.28 info
Change: -$0.466 (-27%) info
Market Cap: $180.047M info
ADCT
Nov 09, 2026, 7:30 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $1.28 info
Change: -$0.300 (-19%) info
Market Cap: $180.047M info
ADCT
Nov 04, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.28 info
Change: -$0.440 (-26%) info
Market Cap: $180.047M info
ADCT
Nov 03, 2026, 5:02 PM EST
Filing Type: S-4
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $1.28 info
Change: -$0.270 (-17%) info
Market Cap: $180.047M info
ADCT
Oct 13, 2026, 6:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $1.28 info
Change: -$0.540 (-30%) info
Market Cap: $180.047M info
ADCT
Oct 08, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $1.28 info
Change: -$0.050 (-4%) info
Market Cap: $180.047M info
ADCT
Aug 13, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $1.28 info
Change: +$0.2208 (+21%) info
Market Cap: $180.047M info
ADCT
Aug 13, 2026, 9:14 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.19
Real-time Price: $1.28 info
Change: +$0.0903 (+8%) info
Market Cap: $180.047M info
ADCT
Aug 13, 2026, 7:38 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $1.28 info
Change: +$0.030 (+2%) info
Market Cap: $180.047M info
ADCT
Jul 02, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.20
Real-time Price: $1.28 info
Change: +$0.0787 (+7%) info
Market Cap: $180.047M info
ADCT
Jun 24, 2026, 7:48 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $1.28 info
Change: +$0.1598 (+14%) info
Market Cap: $180.047M info
ADCT
Jun 04, 2026, 8:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.44
Real-time Price: $1.28 info
Change: -$0.160 (-11%) info
Market Cap: $180.047M info
ADCT
Jun 03, 2026, 4:53 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1.80
Real-time Price: $1.28 info
Change: -$0.520 (-29%) info
Market Cap: $180.047M info
ADCT
Jun 03, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $1.28 info
Change: -$0.620 (-33%) info
Market Cap: $180.047M info
ADCT
Jun 03, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $1.28 info
Change: -$0.620 (-33%) info
Market Cap: $180.047M info
ADCT
Jun 02, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.17
Real-time Price: $1.28 info
Change: -$1.89 (-60%) info
Market Cap: $180.047M info
ADCT
May 04, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.67
Real-time Price: $1.28 info
Change: -$2.39 (-65%) info
Market Cap: $180.047M info
ADCT
May 04, 2026, 7:43 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.75
Real-time Price: $1.28 info
Change: -$2.47 (-66%) info
Market Cap: $180.047M info
ADCT
May 04, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.15
Real-time Price: $1.28 info
Change: -$2.87 (-69%) info
Market Cap: $180.047M info
ADCT
Apr 20, 2026, 8:33 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $4.28
Real-time Price: $1.28 info
Change: -$3.00 (-70%) info
Market Cap: $180.047M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets